MA24062A1 - Heteroatome comprenant des cyclopentano-pyridile oxazolidinones - Google Patents

Heteroatome comprenant des cyclopentano-pyridile oxazolidinones

Info

Publication number
MA24062A1
MA24062A1 MA24463A MA24463A MA24062A1 MA 24062 A1 MA24062 A1 MA 24062A1 MA 24463 A MA24463 A MA 24463A MA 24463 A MA24463 A MA 24463A MA 24062 A1 MA24062 A1 MA 24062A1
Authority
MA
Morocco
Prior art keywords
pyridile
cyclopentano
heteroatome
oxazolidinones
pyridile oxazolidinones
Prior art date
Application number
MA24463A
Other languages
English (en)
Inventor
Stolle Andreas
Bartel Stephan
Ruppelt Martin
Kroll Hein-Peter
Endermann Rainer
Habich Dieter
Guarnieri Walter
Riedl Bernd
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MA24062A1 publication Critical patent/MA24062A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA24463A 1996-01-18 1997-01-14 Heteroatome comprenant des cyclopentano-pyridile oxazolidinones MA24062A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19601627A DE19601627A1 (de) 1996-01-18 1996-01-18 Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone

Publications (1)

Publication Number Publication Date
MA24062A1 true MA24062A1 (fr) 1997-10-01

Family

ID=7783042

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24463A MA24062A1 (fr) 1996-01-18 1997-01-14 Heteroatome comprenant des cyclopentano-pyridile oxazolidinones

Country Status (21)

Country Link
US (1) US5869659A (fr)
EP (1) EP0785201A1 (fr)
JP (1) JPH09202787A (fr)
KR (1) KR970059170A (fr)
AU (1) AU1012397A (fr)
BG (1) BG101139A (fr)
BR (1) BR9700716A (fr)
CA (1) CA2195177A1 (fr)
CZ (1) CZ15897A3 (fr)
DE (1) DE19601627A1 (fr)
EE (1) EE9700020A (fr)
HU (1) HU9700152D0 (fr)
IL (1) IL120016A0 (fr)
MA (1) MA24062A1 (fr)
NO (1) NO970210L (fr)
PL (1) PL317985A1 (fr)
SG (1) SG50001A1 (fr)
SK (1) SK6997A3 (fr)
TN (1) TNSN97010A1 (fr)
TR (1) TR199700039A2 (fr)
ZA (1) ZA97393B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562844B2 (en) 1998-01-23 2003-05-13 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
US7002020B1 (en) 1998-01-23 2006-02-21 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
BR9907183A (pt) 1998-01-23 2003-06-10 Versicor Inc Colet neas combinatórias de oxazolidinona, composições e processos de preparação
AU753988B2 (en) 1998-06-05 2002-10-31 Astrazeneca Ab Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
NZ516853A (en) 1999-07-28 2003-11-28 Upjohn Co Oxazolidinones and their use as anti-infectives
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
US6514529B2 (en) 2000-03-22 2003-02-04 Pharmacia & Upjohn Company Oxazolidinone tablet formulation
MY127336A (en) * 2000-03-22 2006-11-30 Upjohn Co Container for linezolid iv solution
GB0009803D0 (en) * 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
DK1301207T3 (da) 2000-06-30 2005-10-10 Pharmacia & Upjohn Co Llc Sammensætninger til behandling af bakterieinfektioner indeholdende en oxazolidinonforbindelse, sulbactam og ampicillin
US6423844B1 (en) 2001-06-06 2002-07-23 The United States Of America As Represented By The Secretary Of The Navy Process for making 1,2,4-triazolo[4,3-a][1,3,5]triazine-3,5,7-triamine
AR038536A1 (es) * 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
US7141588B2 (en) * 2002-02-25 2006-11-28 Pfizer, Inc. N-aryl-2-oxazolidinone-5-carboxamides and their derivatives
WO2004014897A1 (fr) * 2002-08-12 2004-02-19 Pharmacia & Upjohn Company Llc N-aryl-2-oxazolidinones et leurs derives
AR042086A1 (es) * 2002-11-21 2005-06-08 Upjohn Co N-aril-2- oxazolidinon -5- carboxamidas y sus derivados, usados como agentes antibacterianos
JP2006516991A (ja) * 2003-02-07 2006-07-13 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 抗菌剤
EP1594494A1 (fr) * 2003-02-07 2005-11-16 Warner-Lambert Company LLC Derives d'oxazolidinone n-substitues par un noyau bicyclique, utilises comme agents antibacteriens
US7012088B2 (en) * 2003-02-24 2006-03-14 Pharmacia & Upjohn Company Indolone oxazolidinones and derivatives thereof
US20040204463A1 (en) * 2003-04-01 2004-10-14 Harris Christina Renee N-aryl-2-oxazolidinone-5-carboxamides and their derivatives
US7304050B2 (en) * 2003-09-16 2007-12-04 Pfizer Inc. Antibacterial agents
WO2005082900A2 (fr) * 2004-01-28 2005-09-09 Pharmacia & Upjohn Company Llc Amidoxines d'oxazolidinone utilisees en tant qu'agents antibacteriens
US20080262056A1 (en) * 2004-08-06 2008-10-23 Pfizer Inc Oxindole Oxazolidinones as Antibacterial Agents
ES2627352T3 (es) 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
BR112012009751A2 (pt) 2009-10-26 2020-09-24 Signal Pharmaceuticals, Llc métodos de síntese e purificação de heteroarila
TWI758746B (zh) 2011-10-19 2022-03-21 美商標誌製藥公司 以tor激酶抑制劑治療癌症
MY169749A (en) 2011-12-02 2019-05-15 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
ES2742398T3 (es) 2012-02-24 2020-02-14 Signal Pharm Llc Métodos para tratar el cáncer de pulmón no microcítico usando una terapia de combinación de inhibidores de TOR quinasa
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
TW201441227A (zh) 2013-01-16 2014-11-01 Signal Pharm Llc 經取代吡咯并嘧啶化合物、其組合物及其治療方法
US9358232B2 (en) 2013-04-17 2016-06-07 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
BR112015026247B1 (pt) 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc Uso de compostos em combinação com um análogo de citidina, composição farmacêutica que os compreende, e kit
SG11201508527VA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
CA2909625C (fr) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Polytherapie comprenant un inhibiteur de kinase tor et un compose de quinazolinone substitue en 5 pour le traitement du cancer
WO2014172425A1 (fr) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Traitement du cancer par des dihydropyrazino-pyrazines
EP2986298A1 (fr) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Traitement du cancer par des dihydropyrazino-pyrazines
CN113831345A (zh) 2013-05-29 2021-12-24 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160880A1 (fr) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Formes solides comprenant 1-éthyl-7-(2-méthyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1h)-one, et co-formateur, compositions et procédés d'utilisation de ces dernières
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
EP3131552B1 (fr) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Méthodes de traitement du cancer à l'aide d'une polythérapie avec des inhibiteurs de la kinase tor
EA201790189A1 (ru) 2014-07-14 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
AU2018289539B2 (en) 2017-06-22 2024-07-04 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705799A (en) * 1983-06-07 1987-11-10 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl benzenes useful as antibacterial agents
US4985429A (en) * 1987-10-09 1991-01-15 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
US4965268A (en) * 1987-10-09 1990-10-23 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
US4801600A (en) * 1987-10-09 1989-01-31 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
US4921869A (en) * 1987-10-09 1990-05-01 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
US4942183A (en) * 1987-10-16 1990-07-17 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents
US5254577A (en) * 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5164510A (en) * 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
DE68918792T2 (de) 1988-09-15 1995-03-30 Upjohn Co 5-Indolinyl-5-beta-amidomethyloxazolidin-2-one, 3-(substituierte kondensierte)phenyl-5-beta amidomethyloxazolidin-2-one und 3-(Nitrogen-substituierte)phenyl-5-beta-amidomethyloxazolidin-2-one.
JP2679745B2 (ja) * 1989-06-29 1997-11-19 明治製菓株式会社 アゾール誘導体及びそれらを有効成分とする抗潰瘍剤
JP2669579B2 (ja) * 1991-10-23 1997-10-29 エーザイ株式会社 オキサゾリドン誘導体
DE4332384A1 (de) 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
TW286317B (fr) * 1993-12-13 1996-09-21 Hoffmann La Roche
DE4425612A1 (de) * 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone

Also Published As

Publication number Publication date
CZ15897A3 (en) 1997-08-13
AU1012397A (en) 1997-07-24
MX9700388A (es) 1997-07-31
TNSN97010A1 (fr) 2005-03-15
IL120016A0 (en) 1997-04-15
EE9700020A (et) 1997-08-15
HU9700152D0 (en) 1997-03-28
NO970210D0 (no) 1997-01-17
TR199700039A2 (tr) 1997-08-21
SK6997A3 (en) 1997-09-10
EP0785201A1 (fr) 1997-07-23
DE19601627A1 (de) 1997-07-24
CA2195177A1 (fr) 1997-07-19
KR970059170A (ko) 1997-08-12
JPH09202787A (ja) 1997-08-05
PL317985A1 (en) 1997-07-21
ZA97393B (en) 1997-07-17
NO970210L (no) 1997-07-21
BR9700716A (pt) 1998-10-06
BG101139A (en) 1998-04-30
SG50001A1 (en) 1998-06-15
US5869659A (en) 1999-02-09

Similar Documents

Publication Publication Date Title
MA24062A1 (fr) Heteroatome comprenant des cyclopentano-pyridile oxazolidinones
FR2746302B1 (fr) Compositions cosmetiques comprenant des nanopigments
DE69721098D1 (de) Entwicklungsgerät
DE69720097D1 (de) Entwicklungsgerät
NO985294D0 (no) Kontrastmidler
ZA986360B (en) Tricyclically substituted oxazolidinones
IT1291486B1 (it) Corpo portante.
DK0800783T3 (da) Gulvrenseapparat
ZA981579B (en) Oxazolidinones
NL1001127C1 (nl) Bevestigingsinrichting.
FR2718478B1 (fr) Plinthe démontable.
DE59710679D1 (de) Lüfter
TR199501336A2 (tr) Talim tertibati.
FR2746301B1 (fr) Compositions cosmetiques comprenant des nanopigments
FI3488U1 (fi) Pitolaite
IT237397Y1 (it) Elettrodomestico
DE69709700D1 (de) Kontrastmittel
DE59509813D1 (de) Substituierte oxazoline
FR2724100B1 (fr) Oreiller de soutien.
FR2716348B1 (fr) Coiffe réglable.
IT1287807B1 (it) Dispositivo di fissaggio di corpo rotante.
FR2721514B1 (fr) Compositions thérapeutiques comprenant des 3-phényl-3-hydroxypipéridines.
ES1035520Y (es) Almohada compleja.
ITBO940383A0 (it) Apparecchio magneto-terapeutico.
ITSV970017A0 (it) Dispositivo sterilizzatore perfezionato.